YDYibin Deng

Yibin Deng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yibin Deng has a total of 35 co-authors. Here are the top co-authors by number of shared publications:

  • Junxuan Lü

    Department of Pharmacology, Pennsylvania State University College of Medicine, Hershey, USA

    4 shared publications
  • Lei Wang

    Laboratory of Cancer Genetics, The University of Minnesota Hormel Institute, Austin, MN, 55912, USA

    4 shared publications
  • Hua Xiong

    Laboratory of Cancer Genetics, The University of Minnesota Hormel Institute, Austin, MN, 55912, USA

    3 shared publications
  • Ji Wang

    Laboratory of Cancer Genetics, The University of Minnesota Hormel Institute, Austin, MN, 55912, USA

    3 shared publications
  • Xiaolan Guo

    Laboratory of Cancer Genetics, The University of Minnesota Hormel Institute, Austin, MN, 55912, USA

    3 shared publications
  • Cheng Jiang

    Department of Pharmacology, Penn State College of Medicine, Hershey, PA, 17033, USA

    2 shared publications

Latest Publications

  • Open Access

    Targeting IRES-Mediated p53 Synthesis for Cancer Diagnosis and Therapeutics

    by Bai Ji, Benjamin R. E. Harris, Yahui Liu, Yibin Deng, Sergio A. Gradilone, Margot P. Cleary, Jianhua Liu, Da-Qing Yang

    While translational regulation of p53 by the internal ribosome entry site (IRES) at its 5′-untranslated region following DNA damage has been widely accepted, the detailed mechanism underlying the translational control of p53 by its IRES sequence is still poorly understood. In this review, we will focus on the latest progress in identifying novel regulatory proteins of the p53 IRES and in uncovering the functional connection between defective IRES-mediated p53 translation and tumorigenesis. We will also discuss how these findings may lead to a better understanding of the process of oncogenesis and open up new avenues for cancer diagnosis and therapeutics.


  • Open Access

    Co-targeting hexokinase 2-mediated Warburg effect and ULK1-dependent autophagy suppresses tumor growth of PTEN- and TP53- deficiency-driven castration-resistant prostate cancer

    by Lei Wang, Ji Wang, Hua Xiong, Fengxia Wu, Tian Lan, Yingjie Zhang, Xiaolan Guo, Huanan Wang, Mohammad Saleem, Cheng Jiang, et al.


  • Open Access

    Inhibition of glycolytic enzyme hexokinase II (HK2) suppresses lung tumor growth

    by Huanan Wang, Lei Wang, Yingjie Zhang, Ji Wang, Yibin Deng, Degui Lin

    The most common genetic changes identified in human NSCLC are Kras mutations (10–30 %) and p53 mutation or loss (50–70 %). Moreover, NSCLC with mutations in Kras and p53 poorly respond to current therapies, so we are trying to find a new target for the treatment strategies. Flow cytometry, crystal violet staining and immunoblotting were used to assess cell cycle arrest, proliferation and apoptosis in lung cancer cell lines after 2-DG treatment and lentivirus infection by shRNA knock down. IHC and western blotting were carried for NSG xenograft model with 2-DG treatment and lentivirus infection by shRNA knock down. Knocking down Kras down-regulated the glycolytic enzyme hexokinase II (HK2) in KP2 (mouse lung cancer cell line with Kras mutation and p53 deletion) and H23 (human lung cancer cell line with Kras mutation and p53 mutation) cell lines. Genetic studies revealed that HK2 was required for the human and mouse lung cancer cell growth in vitro and in vivo. Our pharmacological studies confirmed that 2-DG, an inhibitor of HK2, inhibited human and mouse lung cancer cell growth through inducing cell apoptosis and autophagy. HK2 is a promising treatment target for NSCLC with Kras activating and p53 function loss.


  • Methylseleninic Acid Superactivates p53-Senescence Cancer Progression Barrier in Prostate Lesions of Pten-Knockout Mouse

    by Lei Wang, Xiaolan Guo, Ji Wang, Cheng Jiang, Maarten C. Bosland, Junxuan Lü, Yibin Deng

    Monomethylated selenium (MM-Se) forms that are precursors of methylselenol, such as methylseleninic acid (MSeA), differ in metabolism and anticancer activities in preclinical cell and animal models from seleno-methionine that had failed to exert preventive efficacy against prostate cancer in North American men. Given that human prostate cancer arises from precancerous lesions such as high-grade prostatic intraepithelial neoplasia (HG-PIN), which frequently have lost phosphatase and tensin homolog (PTEN) tumor suppressor permitting phosphatidylinositol-3-OH kinase (PI3K)–protein kinase B (AKT) oncogenic signaling, we tested the efficacy of MSeA to inhibit HG-PIN progression in Pten prostate-specific knockout (KO) mice and assessed the mechanistic involvement of p53-mediated cellular senescence and of the androgen receptor (AR). We observed that short-term (4 weeks) oral MSeA treatment significantly increased expression of P53 and P21Cip1 proteins and senescence-associated-β-galactosidase staining, and reduced Ki67 cell proliferation index in Pten KO prostate epithelium. Long-term (25 weeks) MSeA administration significantly suppressed HG-PIN phenotype, tumor weight, and prevented emergence of invasive carcinoma in Pten KO mice. Mechanistically, the long-term MSeA treatment not only sustained P53-mediated senescence, but also markedly reduced AKT phosphorylation and AR abundance in the Pten KO prostate. Importantly, these cellular and molecular changes were not observed in the prostate of wild-type littermates which were similarly treated with MSeA. Because p53 signaling is likely to be intact in HG-PIN compared with advanced prostate cancer, the selective superactivation of p53-mediated senescence by MSeA suggests a new paradigm of cancer chemoprevention by strengthening a cancer progression barrier through induction of irreversible senescence with additional suppression of AR and AKT oncogenic signaling. Cancer Prev Res; 9(1); 35–42. ©2015 AACR.


  • Open Access

    Targeting hexokinase 2 in castration-resistant prostate cancer

    by Yibin Deng, Junxuan Lu

    Aerobic glycolysis, known as the Warburg effect, is one of the hallmarks of cancer cells. We recently reported that the hexokinase 2 (HK2)-mediated Warburg effect is required for castration-resistant prostate cancer that is driven by Pten/p53 deficiency, suggesting that HK2 might be a therapeutic target for prostate cancer patients carrying PTEN and p53 mutations.


  • Open Access

    Hexokinase 2-Mediated Warburg Effect Is Required for PTEN- and p53-Deficiency-Driven Prostate Cancer Growth

    by Lei Wang, Hua Xiong, Fengxia Wu, Yingjie Zhang, Ji Wang, Liyan Zhao, Xiaolan Guo, Li-Ju Chang, Yong Zhang, M. James You, et al.


  • Methylseleninic Acid Suppresses Pancreatic Cancer Growth Involving Multiple Pathways

    by Lei Wang, Hongbo Hu, Zhe Wang, Hua Xiong, Yan Cheng, Joshua Dezhong Liao, Yibin Deng, Junxuan Lü

    As a potential novel agent for treating pancreatic cancer, methylseleninic acid (MSeA) was evaluated in cell culture and xenograft models. Results showed that MSeA induced G1 cell cycle arrest and apoptosis in a majority of human and mouse pancreatic cancer cell lines, but G2 arrest in human PANC-1 and PANC-28 cell lines. In contrast to our previous finding in human prostate cancer LNCaP cells having a lack of P53 activation by MSeA, induction of G2 arrest in PANC-1 cells was accompanied by increased mutant P53 Ser15 phosphorylation, upregulation of P53-targets P21Cip1 and GADD45 and G2 checkpoint kinase (Chk2) activation, suggestive of DNA damage responses. A rapid inhibition of AKT phosphorylation was followed by reduced mTOR signaling and increased autophagy in PANC-1 cells attenuating caspase-mediated apoptosis execution. Furthermore, daily oral treatment with MSeA (3 mg Se/kg body weight) significantly suppressed growth of subcutaneously inoculated PANC-1 xenograft in SCID mice. Immunohistochemical analyses detected increased p-Ser15 P53, P21Cip1, pS139-H2AX (DNA damage responses), and caspase-3 cleavage and decreased pSer473AKT and Ki67 proliferative index and reduced intratumor vascular density in MSeA-treated xenograft. These results provide impetus for further research of MSeA in the therapy and/or chemoprevention of pancreatic cancer.